Jun 23, 10 03:28PM
|
0 comments
Cytori Therapeutics took a hit when they and investors learned that their device to harvest autologous stem cells from fat for breast reconstruction would require more work, about $10M more. Cytori had been banking on a 510(k) route to market and instead, must submit a pre-market application (PMA), typical of Class III devices, which require [...]
Comments
To add a comment to the original post, click here.
You must be signed in to post a comment.
Sign in nowThere are no comments for this post.